Incidence of thrombo-embolism (TE) during neo-adjuvant chemotherapy in patients (pts) with oesophago-gastric adenocarcinoma (OGC): implications for...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter R. Rulach
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors R. Rulach1, J. Evans1, D. McIntosh1, D. Grose1, G. Fullarton2, M. Forshaw2, C. MacKay2, C. Craig2, J. Graham1
  • 1The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, /
  • 2University Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom, /


Peri-operative cisplatin-based chemotherapy is the standard of care for potentially operable OGC1. OGC is associated with an increased risk of TE2, which may be further increased by potentially thrombogenic cisplatin chemotherapy. Current international guidelines do not recommend prophylactic anticoagulation in the ambulatory setting3. The aim of this retrospective single-centre study was to quantify the frequency and consequences of TE during neo-adjuvant chemotherapy in pts with OGC.